查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2022645

siRNA偶聯物市場：全球產業分析、市場規模、市佔率及2026-2033年預測－依治療領域、研發階段、偶聯物類型、最終用戶、國家及地區分類

siRNA Conjugates Market, By Therapeutic Area, By Development Stage, By Conjugate Type, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 351 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計 siRNA 偶聯物市場在 2025 年將達到 8.1071 億美元，並在 2026 年至 2033 年期間以 15.10% 的複合年成長率成長。

siRNA偶聯物是一種特殊的治療方法，它將小干擾RNA（siRNA）連接到能夠幫助其進入細胞的分子上。這提高了RNA的穩定性，使其更容易到達目標並被細胞吸收。科學家可以利用這種方法來惰性特定基因，更有效地治療多種疾病，同時減少副作用。由於遞送方法的改進、RNA治療方法研究的進展以及對精準醫療投入的增加，這類治療方法的市場正在不斷成長。

由於遞送技術的進步和對精準標靶治療方法日益成長的需求，siRNA偶聯物市場正在不斷擴張。這些偶聯物能夠將siRNA直接遞送至特定細胞並精準定序基因，從而治療多種疾病。更高的穩定性、更強的標靶化能力和更快的細胞內吸收速度，使這些治療方法更加有效和安全，最終改善治療效果並最大限度地減少副作用。 2025年，Alnilam Pharmaceuticals宣布將投資2.5億美元，大幅擴建其在美國的生產基地，用於建造siRNA藥物的專用製造地線，這反映了市場對標靶基因靜默療法日益成長的需求，並旨在提高RNAi療法遞送的精準度和速度。這些進展表明，siRNA偶聯物在精準醫療領域的應用正在不斷擴展。

siRNA偶聯物市場 - 市場動態

人們對標靶治療的認知不斷提高，正在推動市場需求。

標靶治療需求不斷成長的主要促進因素之一是先進藥物遞送平台、精準醫療策略以及新一代生物製劑（例如siRNA偶聯物和抗體藥物複合體(ADC)）的日益普及。近期進展包括標靶小分子抑制劑、新型免疫查核點抑制劑和抗體藥物複合體，以及加速藥物研發過程的人工智慧驅動工具。這些趨勢旨在最大限度地減少副作用，改善患者預後，並支持現代技術主導的醫療保健格局。在2025年底至2026年初，Alnylam Pharmaceuticals, Inc. 繼續推進RNA干擾。這些進展凸顯了siRNA偶聯物在精準醫療中日益擴大的作用，而這種作用的驅動力是創新、臨床進步以及更安全、更有效的治療方法。

siRNA偶聯物市場－市場細分分析：

全球siRNA偶聯物市場按治療領域、開發階段、偶聯物類型、最終用戶和地區進行細分。

心血管、中樞神經系統、慢性疾病、腫瘤和罕見疾病領域是siRNA偶聯物市場的關鍵領域。這些治療方法對於在複雜的病理條件下進行精準的基因靜默至關重要。這些領域研發活動的活性化以及對標靶治療日益成長的需求正在推動市場需求。例如，美國國立衛生研究院 (NIH) 發布的2023年全球細胞和基因治療趨勢回顧報告顯示，全球已有超過100種先進的基因、細胞和RNA治療產品核准，另有超過3700種治療方法處於臨床和臨床前開發階段，這反映出與往年相比，創新治療方法的開發顯著擴展。報告強調，截至2023年底，全球先進治療候選藥物的研發管線涵蓋了基因、細胞和RNA等多種治療模式，涉及數千個計畫。這些趨勢顯示siRNA偶聯物和精準醫療在全球範圍內正快速發展。

從應用角度來看，醫院、研究機構和專科診所憑藉其在患者照護、臨床試驗和專科治療方面的能力，在siRNA偶聯物市場中發揮著至關重要的作用。醫院能夠實現siRNA治療方法的廣泛臨床應用和實施，而研究機構則專注於新型偶聯物的發現、開發和最佳化。例如，根據歐盟委員會的數據，到2023年，歐盟共有約230萬張醫院床位，平均每10萬居民擁有511張床位，這反映了各成員國醫療資源的分佈。 2013年至2023年間，歐盟的醫院床位數量減少了約7%，儘管葡萄牙、西班牙和羅馬尼亞等一些國家的人均床位數量略有增加。這凸顯了醫療基礎設施對於siRNA偶聯物療法發展的重要性。

siRNA偶聯物市場—區域分析

從區域來看，siRNA偶聯物市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲五個區域。北美憑藉其先進的醫療基礎設施、強大的研發能力以及精準醫療的高普及率，在市場中佔有舉足輕重的地位。對標靶治療日益成長的需求、對RNA治療方法投資的增加以及有利的法規結構，進一步鞏固了該地區的重要作用。例如，根據美國政府預測，截至2025年6月，全球將有超過120項針對黑色素瘤、胰臟癌、腦瘤、肺癌和乳癌的RNA癌症疫苗臨床試驗正在進行中，這反映了研究活動活性化。預計到2025年中期，RNA癌症疫苗將取得突破性成果，例如黑色素瘤復發率降低44%，以及在其他癌症類型中誘發免疫反應。由於先進的基礎設施、強大的研究活動以及基於 RNA 的治療方法的重大進展，這些進步凸顯了北美在 siRNA 偶聯物市場的領先地位。

亞太地區正經歷市場擴張，這主要得益於醫療保健支出的成長和人們對先進治療方法認知度的提高。例如，根據IBEF.org的數據，印度醫療保健產業市場規模在2023年預計約為3,720億美元，近年來成長顯著，這得益於公共和私營部門的擴張。 IBEF指出，印度醫療保健工作者人數將在2024-2025會計年度超過600萬，政府已在2025-2026會計年度聯邦預算中為該行業撥款約99858億盧比（約合115億美元）。因此，這些因素，加上投資和人才的增加，凸顯了亞太地區在醫療保健進步和先進治療方法應用方面將發揮越來越重要的作用。

歐洲siRNA偶聯物市場－各國概況

在合作研究舉措、統一的監管標準以及對RNA創新日益重視的推動下，歐洲正在擴大其在siRNA偶聯物市場中的作用。例如，2024年4月，Wave Life Sciences Ltd.（新加坡/歐洲）透過多個siRNA和RNA編輯計畫增強了其RNA藥物平台。這包括將GalNAc偶聯的INHBE siRNA（WVE-007）推進至臨床開發階段，以及擴大針對α-1抗胰蛋白酶缺乏症的RNA編輯候選化合物（WVE-006）的臨床試驗，凸顯了RNA療法領域不斷成長的創新能力和臨床進展。這些進展表明，在創新、臨床進展和合作研究的推動下，歐洲在siRNA療法領域正處於日益強大的領導地位。

目錄

第1章：siRNA偶聯物市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：siRNA偶聯物市場的主要趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：siRNA偶聯物的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：siRNA偶聯物市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：siRNA偶聯物市場概覽

  • siRNA偶聯物市場佔有率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 siRNA偶聯物市場：依治療領域分類

  • 概述
    • 按治療區域分類的市佔率分析
    • 罕見疾病
    • 腫瘤學
    • 慢性病
    • 中樞神經系統
    • 心血管系統

第8章：siRNA偶聯物市場：依研發階段分類

  • 概述
    • 細分市場佔有率分析：依發展階段分類
    • 臨床試驗
      • 第一階段
      • 第二階段
      • 第三階段
    • 商業化
    • 臨床前階段
      • 體內
      • In Vitro

第9章 siRNA偶聯物市場：以偶聯物類型分類

  • 概述
    • 細分市場佔有率分析：依共軛類型
    • 胜肽
    • 脂質奈米顆粒
    • GalNAc

第10章：siRNA偶聯物市場：依最終用戶分類

  • 概述
    • 細分市場佔有率分析：依發展階段分類
    • 專科診所
    • 研究機構
    • 醫院

第11章 siRNA偶聯物市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章：主要供應商分析：siRNA偶聯物產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • WuXi XDC
    • Creative Biogene
    • Bachem
    • LGC Biosearch Technologies
    • Sinopep
    • Organix
    • CD Formulation
    • Hitgen
    • Alnylam Pharmaceuticals, Inc.
    • Amerigo Scientific
    • BOCSCI Inc.
    • Creative Biolabs
    • Bio-Synthesis Inc
    • Creative Peptide
    • GenScript
    • Suzhou Biosyntech
    • Arrowhead Pharmaceuticals, Inc.
    • Silence Therapeutics plc
    • Dicerna Pharmaceuticals, Inc.
    • Wave Life Sciences Ltd.
    • Sirnaomics, Inc.
    • Quark Pharmaceuticals, Inc.
    • Others

第13章：分析師的綜合視角

簡介目錄
Product Code: ANV6369

siRNA Conjugates Market size was valued at US$ 810.71 Million in 2025, expanding at a CAGR of 15.10% from 2026 to 2033.

siRNA conjugates are special treatments that attach small interfering RNA (siRNA) to molecules that help deliver it into cells. This makes the RNA more stable, easier to target, and better absorbed by cells. They allow scientists to turn off specific genes to treat different diseases more effectively, with fewer side effects. The market for these therapies is growing because of better delivery methods, more research in RNA-based treatments, and increased investment in precision medicine.

The siRNA conjugates market is expanding in delivery technologies and a rising need for precise, targeted treatments. These conjugates transport small interfering RNA directly to specific cells, allowing genes to be silenced accurately to treat various diseases. Better stability, improved targeting, and enhanced cellular uptake make these therapies more effective and safer, improving treatment outcomes and minimizing side effects. In 2025, Alnylam Pharmaceuticals, Inc. announced a major expansion of its U.S. manufacturing footprint with a $250 million investment to build dedicated siRNA drug production capabilities, aimed at enhancing precision and speed in delivering its RNAi therapeutics to patients, reflecting growing demand for targeted gene-silencing treatments. These advances underscore the growing adoption of siRNA conjugates in precision medicine.

siRNA Conjugates Market- Market Dynamics

Increasing Awareness About Targeted Therapies To Propel Market Demand

One primary driver of the growing demand for targeted therapies is fueled by the increasing use of advanced drug delivery platforms, precision medicine strategies, and next-generation biologics such as siRNA conjugates and antibody-drug conjugates. Recent advances include targeted small-molecule inhibitors, novel immune checkpoint and antibody-drug conjugates, and AI-driven tools to speed drug discovery. These trends aim to minimize side effects, improve patient outcomes, and support a modern, technology-driven healthcare landscape. In late 2025 and early 2026, Alnylam Pharmaceuticals, Inc. continued to advance its RNAi therapeutic platform, reporting financial results for 2025 that included robust growth in product revenues and outlining 2026 pipeline goals with multiple clinical readouts and new study initiations as part of its strategy to deliver targeted RNA interference treatments for genetic and other diseases. These developments underscore siRNA conjugates' growing role in precision medicine, driven by innovation, clinical advances, and safer, more effective therapies.

siRNA Conjugates Market- Segmentation Analysis:

The Global siRNA Conjugates Market is segmented on the basis of Therapeutic Area, Development Stage, Conjugate Type, End User, and Region.

The cardiovascular, central nervous system, chronic disease, oncology, and rare disease segments are key areas in the siRNA conjugates market, as these therapies are critical for precise gene silencing in complex conditions. Growing research and development efforts, along with the rising need for targeted treatments in these areas, are driving demand. For instance, in 2023, according to the review on the global cell and gene therapy landscape by NIH Govt., more than 100 advanced gene, cell, and RNA therapy products were approved worldwide, with over 3,700 additional therapies in clinical and preclinical development, reflecting a significant expansion in innovative treatment development compared with previous years. The review highlights that by the end of 2023, the global pipeline of advanced therapeutic candidates encompassed thousands of programs across gene, cell, and RNA modalities. These trends highlight the rapid growth of siRNA conjugates and precision medicine globally.

From a usage perspective, hospitals, research institutes, and specialty clinics play a key role in the siRNA conjugates market due to their capacity for patient care, clinical trials, and specialized treatments. Hospitals enable broad therapeutic application and administration of siRNA-based therapies, while research institutes focus on discovery, development, and optimization of new conjugates. For instance, in 2023, according to the European Commission, there were about 2.3 million hospital beds available across the European Union, with an average of 511 beds per 100,000 inhabitants-figures reflecting the distribution of care capacity across member states. Between 2013 and 2023, EU hospital beds fell by ~7%, though countries like Portugal, Spain, and Romania saw slight per-capita increases. This underscores the importance of healthcare infrastructure in advancing siRNA conjugate therapies.

siRNA Conjugates Market- Geographical Insights

By region, the siRNA conjugates market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America's significant position in the market is due to advanced healthcare infrastructure, research capabilities, and high adoption of precision medicine. Rising demand for targeted therapies, growing investment in RNA-based treatments, and supportive regulatory frameworks reinforce the region's prominent role. For instance, in June 2025, according to the US govt., over 120 global clinical trials of RNA cancer vaccines are underway across melanoma, pancreatic, brain, lung, and breast cancers, reflecting increased research activity. By mid-2025, RNA cancer vaccines showed breakthrough results, including a 44% reduction in melanoma recurrence and immune responses in other cancers. These developments underscore North America's leadership in the siRNA conjugates market, driven by advanced infrastructure, robust research, and significant progress in RNA-based therapies.

The Asia-Pacific region is expanding due to rising healthcare spending and greater awareness of advanced therapeutic modalities. For instance, in 2023, according to IBEF.org, India's healthcare sector was valued at about US $372 billion, having grown substantially over recent years and supported by both public and private expansion. IBEF highlights that in 2024-25, the healthcare workforce in India exceeded 6 million professionals, and the government allocated nearly Rs. 99,858 crore (US $11.50 billion) to the sector in the Union Budget for 2025-26. As a result, these factors highlight the Asia-Pacific region's growing role in advancing healthcare and adoption of advanced therapies, supported by investment and workforce expansion.

Europe siRNA Conjugates Market- Country Insights

Europe is enhancing its role in the siRNA conjugates market, driven by joint research initiatives, aligned regulatory standards, and increased focus on RNA-based innovations. For instance, in April 2024, Wave Life Sciences Ltd. (Singapore/Europe) advanced its RNA medicines platform with multiple siRNA and RNA editing programs, including its GalNAc-conjugated INHBE siRNA (WVE-007) entering clinical development and expanded trials for its RNA editing candidate (WVE-006) in alpha-1 antitrypsin deficiency-highlighting growing innovation and clinical momentum in RNA-based therapeutics. These developments underscore Europe's growing leadership in siRNA therapeutics, driven by innovation, clinical progress, and collaborative research efforts.

siRNA Conjugates Market- Competitive Landscape:

The siRNA conjugates market is highly competitive, with key players like Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Silence Therapeutics plc, Dicerna Pharmaceuticals, Inc., Wave Life Sciences Ltd., Sirnaomics, Inc., and Quark Pharmaceuticals, Inc. driving innovation in targeted therapies. These companies focus on enhancing precision delivery, improving efficacy, and minimizing off-target effects across multiple therapeutic areas. Investments in partnerships, R&D, and clinical trials are expanding pipelines and advancing next-generation siRNA technologies. In August 2024, Sirnaomics, Inc. entered a strategic partnership with Gore Range Capital LLC to establish Sagesse Bio, Inc., a joint venture aimed at advancing its RNAi therapeutics into aesthetic medicine and accelerating clinical development of its lead siRNA candidates for body contouring and focal fat reduction, highlighting a broader push to expand RNA-based innovations into new therapeutic areas.

Recent Developments:

In 2025, Arrowhead Pharmaceuticals, Inc. announced the FDA approval and commercial launch of REDEMPLO(R) (plozasiran) - its first-ever marketed siRNA therapeutic for adults with familial chylomicronemia syndrome, marking the company's transition from development to commercial availability of targeted RNAi medicines.

In June 2025, Sinopep-Allsino Biopharmaceutical Co., Ltd. entered into a strategic cooperation agreement with Vazyme, establishing a joint venture to advance synthetic biology platforms and expand technological capabilities in biopharma applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SIRNA CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • WuXi XDC
  • Creative Biogene
  • Bachem
  • LGC Biosearch Technologies
  • Sinopep
  • Organix
  • CD Formulation
  • Hitgen
  • Alnylam Pharmaceuticals, Inc.
  • Amerigo Scientific
  • BOCSCI Inc.
  • Creative Biolabs
  • Bio-Synthesis Inc
  • Creative Peptide
  • GenScript
  • Suzhou Biosyntech
  • Arrowhead Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Dicerna Pharmaceuticals, Inc.
  • Wave Life Sciences Ltd.
  • Sirnaomics, Inc.
  • Quark Pharmaceuticals, Inc.
  • Others

GLOBAL SIRNA CONJUGATES MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033

  • Rare Disease
  • Oncology
  • Chronic Disease
  • Central Nervous System
  • Cardiovascular

GLOBAL SIRNA CONJUGATES MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2020 - 2033

  • Clinical Trials
  • Phase I
  • Phase II
  • Phase III
  • Commercial
  • Preclinical
  • In Vivo
  • In Vitro

GLOBAL SIRNA CONJUGATES MARKET, BY CONJUGATE TYPE- MARKET ANALYSIS, 2020 - 2033

  • Peptide
  • Lipid Nanoparticle
  • GalNAc

GLOBAL SIRNA CONJUGATES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Specialty Clinics
  • Research Institutes
  • Hospitals

GLOBAL SIRNA CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. siRNA Conjugates Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. siRNA Conjugates Market Snippet by Therapeutic Area
    • 2.1.2. siRNA Conjugates Market Snippet by Development Stage
    • 2.1.3. siRNA Conjugates Market Snippet by Conjugate Type
    • 2.1.4. siRNA Conjugates Market Snippet by End User
    • 2.1.5. siRNA Conjugates Market Snippet by Country
    • 2.1.6. siRNA Conjugates Market Snippet by Region
  • 2.2. Competitive Insights

3. siRNA Conjugates Key Market Trends

  • 3.1. siRNA Conjugates Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. siRNA Conjugates Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. siRNA Conjugates Market Opportunities
  • 3.4. siRNA Conjugates Market Future Trends

4. siRNA Conjugates Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. siRNA Conjugates Market : Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. siRNA Conjugates Market Landscape

  • 6.1. siRNA Conjugates Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. siRNA Conjugates Market - By Therapeutic Area

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
    • 7.1.2. Rare Disease
    • 7.1.3. Oncology
    • 7.1.4. Chronic Disease
    • 7.1.5. Central Nervous System
    • 7.1.6. Cardiovascular

8. siRNA Conjugates Market - By Development Stage

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Development Stage, 2025 & 2033 (%)
    • 8.1.2. Clinical Trials
      • 8.1.2.1. Phase I
      • 8.1.2.2. Phase II
      • 8.1.2.3. Phase III
    • 8.1.3. Commercial
    • 8.1.4. Preclinical
      • 8.1.4.1. In Vivo
      • 8.1.4.2. In Vitro

9. siRNA Conjugates Market - By Conjugate Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Conjugate Type, 2025 & 2033 (%)
    • 9.1.2. Peptide
    • 9.1.3. Lipid Nanoparticle
    • 9.1.4. GalNAc

10. siRNA Conjugates Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Development Stage, 2025 & 2033 (%)
    • 10.1.2. Specialty Clinics
    • 10.1.3. Research Institutes
    • 10.1.4. Hospitals

11. siRNA Conjugates Market - By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. siRNA Conjugates Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. siRNA Conjugates Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. siRNA Conjugates Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. siRNA Conjugates Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. siRNA Conjugates Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- siRNA Conjugates Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. WuXi XDC
    • 12.2.2. Creative Biogene
    • 12.2.3. Bachem
    • 12.2.4. LGC Biosearch Technologies
    • 12.2.5. Sinopep
    • 12.2.6. Organix
    • 12.2.7. CD Formulation
    • 12.2.8. Hitgen
    • 12.2.9. Alnylam Pharmaceuticals, Inc.
    • 12.2.10. Amerigo Scientific
    • 12.2.11. BOCSCI Inc.
    • 12.2.12. Creative Biolabs
    • 12.2.13. Bio-Synthesis Inc
    • 12.2.14. Creative Peptide
    • 12.2.15. GenScript
    • 12.2.16. Suzhou Biosyntech
    • 12.2.17. Arrowhead Pharmaceuticals, Inc.
    • 12.2.18. Silence Therapeutics plc
    • 12.2.19. Dicerna Pharmaceuticals, Inc.
    • 12.2.20. Wave Life Sciences Ltd.
    • 12.2.21. Sirnaomics, Inc.
    • 12.2.22. Quark Pharmaceuticals, Inc.
    • 12.2.23. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us